LifeMD Inc (LFMD)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ
Market Cap: $106.09M
Last updated: Nov 17, 2026 at 11:04 AM ET
LifeMD Inc (LFMD) Stock Forecast
Analysts expect LifeMD (LFMD) to earn -$0.17 per share in the fiscal year ending Dec 31, 2026, on revenue of $204.48M. Of 8 analysts, 8 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 8 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 8
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus turns from a loss to a profit and revenue estimates rise 17.8%.
- Fiscal year ending Dec 31, 2026
- -$0.17
- EPS consensus, revenue $204.48M
- Fiscal year ending Dec 31, 2027
- $0.38
- EPS consensus, revenue $240.78M
- Next report
- Mar 8, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.17 | -$0.22 to -$0.11 | 2 | $204.48M | $189.88M to $209.40M | 7 |
| Dec 31, 2027 | $0.38 | $0.27 to $0.49 | 2 | $240.78M | $208.02M to $260.00M | 8 |
Quarterly Estimates
The EPS consensus rises from -$0.09 for the quarter ending Dec 31, 2026 to $0.09 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.09 | -$0.20 to $0.06 | 10 | $51.69M | $45.18M to $65.10M | 10 |
| Mar 31, 2027 | $0.09 | $0.09 to $0.09 | 1 | $55.59M | $50.66M to $60.28M | 6 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 3 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has turned from a profit of $0.14 to a loss.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.17 | $0.14 | $0.14 | $0.14 | $0.14 | N/A |
| Fiscal year ending Dec 31, 2027 | $0.38 | $0.52 | $0.52 | $0.52 | $0.54 | -29.6% |
| Quarter ending Mar 31, 2027 | $0.09 | $0.11 | $0.11 | $0.11 | $0.13 | -30.8% |
Frequently Asked Questions About LFMD
What is the LFMD stock forecast?
Consensus analyst estimates put LifeMD's EPS at -$0.17 for the fiscal year ending Dec 31, 2026, on revenue of $204.48M. The consensus rating from 8 analysts is Buy.
How do analysts rate LFMD stock?
Of 8 analysts covering LifeMD, 0 rate it Strong Buy, 8 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from LFMD next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.17, with estimates from -$0.22 to -$0.11 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.38, with estimates from $0.27 to $0.49 from 2 analysts.
What revenue do analysts expect from LifeMD next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $204.48M, with estimates from $189.88M to $209.40M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $240.78M, with estimates from $208.02M to $260.00M.
How many analysts cover LFMD?
8 analysts rate LifeMD stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
LFMD pages: Overview, Earnings, Forecast, Financials, Competitors